Could a 5-Day drug course make surgery safer for liver patients with low platelets?
NCT ID NCT06642740
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests whether a 5-day course of avatricopal can safely raise platelet counts in people with chronic liver disease who have low platelets and need surgery. The goal is to see if more patients reach a platelet count of at least 50×10⁹/L on the day of their procedure, which could lower bleeding risks. Researchers will also monitor for side effects like blood clots or bleeding events.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a drug called avatricopal
- What this could lead to
- If it works, avatricopal could offer a way to safely increase platelet counts before surgery in people with chronic liver disease, reducing the need for platelet transfusions.
- What could go wrong
- This is a relatively small, early-stage study, so results may not apply broadly. The drug could cause side effects like thrombotic events, and its long-term safety is not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
108 people
The number who actually took part.
- Started
-
Jun 2024
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with chronic liver disease complicated with thrombocytopenia undergoing elective invasive and minimally invasive surgery were admitted to the experimental group for clinical observation.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Voluntarily join the study and sign the informed consent; * Age ≥18 years old, male or female; * Baseline platelet count \< 50×10\^9/L; * Patients with chronic liver disease undergoing elective invasive and minimally invasive surgery; * No fertility requirements. Exclusion Criteria: * History of arterial or venous thrombosis within 6 months prior to baseline; * Plan to receive platelet transfusion or platelet-containing blood products within 7 days prior to baseline visit; * Anticoagulant or antiplatelet therapy cannot be suspended before surgery according to the standard (low-dose aspirin is allowed to continue); * currently receiving treatment with recombinant human thrombopoietin or thrombopoietin receptor agonists (such as rhTPO, Etopopal, or romipristine); * The subjects had severe arteriosclerosis, cerebral thrombosis tendency, coronary artery stenosis \> 70%; * Patients with a history of arterial or venous thrombosis within 6 months before enrollment; * Patients with known portal vein blood flow velocity \< 10 cm/s or previous portal vein thrombosis within 6 months before enrollment; * Prior to enrollment, any known primary blood history (e.g., immune thrombocytopenia, myelodysplastic syndrome, aplastic anemia); * A known history of hereditary prethrombotic syndrome prior to admission (e.g., VLeiden mutation, prothrombin G20210A mutation, or hereditary antithrombin III (ATIII) deficiency); * A history of major cardiovascular disease within the 6 months prior to enrollment (e.g., aggravated congestive heart failure, arrhythmias known to increase the risk of thromboembolic events \[such as atrial fibrillation\], coronary or peripheral arterial stenting or angioplasty, and coronary or peripheral arterial bypass grafting); * the subject is allergic to avatripopal or any of its excipients; * Exclude vulnerable people with mental disorders and other disabilities * The investigator believes that accompanying medical history may affect the safe completion of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Ditan Hospital,Capital Medical University
Beijing, Beijing Municipality, 100015, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stick-On ultrasound patch could spot liver damage without a specialist
- Bile acid pill may turbocharge liver regrowth after transplant
- Can a simple blood test predict who will get chronic ITP?
- New MRI methods could spot liver damage earlier
- New ultrasound technique aims to better measure liver health
- New MRI dye could sharpen liver lesion detection